Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MDG 1011

Next Previous
X
Search
Drug Profile

MDG 1011

Alternative Names: MDG-1011

Latest Information Update: 24 Aug 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Helmholtz Zentrum Munchen; Max Delbruck Center for Molecular Medicine
  • Developer MediGene AG
  • Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Myelodysplastic syndromes
  • Phase I/II Acute myeloid leukaemia; Multiple myeloma

Most Recent Events

  • 17 Aug 2023 Medigene AG has patent protection for T cell receptor targeting PRAME (PReferentially expressed Antigen of MElanoma) in Europe and China
  • 24 Apr 2023 Final efficacy and adverse events data from a phase I/II trial in Acute myeloid leukaemia and Multiple myeloma released by Medigene AG
  • 11 Apr 2023 Adverse events data from a phase I/II trial in Myelodysplastic syndrome, Multiple myeloma and Acute myeloid leukaemia released by MediGene

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top